SCHEMBL14920262

SCHEMBL14920262

COc1ncccc1-c1ccc2onc(N(C(=O)O)C(=O)O)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.45
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
FFAR4 Q5NUL3 2/20 0.41
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
METAP2 P50579 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
LRRK2 Q5S007 2/20 0.38
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
SCN9A Q15858 1/20 0.37
PTGES2 Q9H7Z7 1/20 0.36
GSK3B P49841 2/20 0.36
EIF4E P06730 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16022001 0.87 HDAC3 (0.40) DHODHHDAC3HDAC1HDAC2HDAC8
SCHEMBL16021419 0.79 NR3C1 (0.47) DHODHHDAC3HDAC1HDAC2HDAC8
SCHEMBL14920445 0.71 MEN1 (0.39) HDAC1HDAC6CA1CA2
SCHEMBL14920522 0.71 FAAH (0.40) CA1CA2SCN9A
SCHEMBL14920203 0.69 ESR1 (0.50)
SCHEMBL14920041 0.68 AMY1A (0.33) DHODHSCN9AKCNH2SCN5A
SCHEMBL2042515 0.68 DHODH (0.58) DHODHHDAC3HDAC1HDAC2HDAC8
SCHEMBL29788287 0.68 DHODH (0.58) DHODHHDAC3HDAC1HDAC2HDAC8
SCHEMBL1509611 0.65 DHODH (0.50) DHODHHDAC3HDAC1HDAC2HDAC8
SCHEMBL1509471 0.65 ERN1 (0.52) DHODHALOX5APFEN1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773641-B1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2017-09-27 EP disclosed
US-9481677-B2 Biaryl ether sulfonamides and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2016-11-01 US disclosed
US-9365578-B2 2016-06-14 US disclosed
US-20140256736-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2014-09-11 US disclosed
EP-2773641-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2014-09-10 EP disclosed
WO-2013064984-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256736-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS TRPV1, TRPV3, TRPV2 DHODH 1442/4885HDAC3 86/4885HDAC1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.